Hi Teri!
Thanks for writing and I'm glad you had a painfree day yesterday--and hopefully a repeat today.
I did read the poster yesterday and just reread it to see if there was a literature citation other than references. I did not realize the poster signified that the research was published in a Journal of some sort.
My husband presents Poster results at national pharmacy conferences, but they are not always then published in Pharmacy/Medical journals with a more global circulation. I was only thinking that for all the practitioners who did not attend the conference and see the poster presentation, will they be privvy to the research results?
The reason this occured to me is that I was recently diagnosed with severe hypnic headaches (rare apparently) and in digging out all published articles on this type of headache since it was first "named" in 1988 (about 20 articles) realized that the articles are seldom in Neurology--they were more often in Cephalgia or journals regarding electroencephalography. It's no wonder that many neurologists, primary care physicians (and patients like me) have never heard of it. Targeted circulation is so important: I was thinking that wider dissemination of the case reports and case surveys might have increased the chances for me and other patients for a much earlier diagnosis, and effective treatment. I suspect hypnic headaches are underdiagnosed, but it's only a guess. If every neurologist used YOUR chart for tracking migraines, diagnosis would occur more quickly, but many insist we use THEIR charts which don't eludicate the pattern.
Anyway, I hope the poster results are dissemenated to physicians who treat migraines far and wide since some are slow to begin prescribing newer therapies for diagoses beyond those "approved" by the labelling. It's a great study with very optimistic results. Since I have migraines, too (and take Depakote ER), I know now that there is yet another related medication (documented to help!) that I can try if Depakote ER becomes intolerable like Topamax did (allergic reaction).
Things are looking up!
Hugs,
Clemmie
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
Dear Teri:
These results are very powerful especially because of the patient group Dr. Krucz selected for the study: "Twenty patients with chronic Migraines who had not responded to other prophylaxis measures were studied". Wow.
Please tell him we thank him profusely for daring to study this particular population, taking the the time to do the data-gathering/analysis and to discuss the mechanizism by which Namenda reduced headache pain. This study will hopefully be published in a major peer-reviewed journal so that more practitioners are informed and are maybe more comfortable prescribing this drug for migraine patients.
Thanks for informing us about this new research, and I hope you are having a pain-free day!
Clemmie
Clemmie,
Thank you for your note. I'll be sure Dr. Krusz sees it.
This study has already been published. I don't know if you went clear to the end of the article, but on the last page, there's a link to the forumla research poster that has been presented to doctors at conferences of the American Headache Soceity and the European Federation of Neurological Societies. Dr. Krusz kindly let me republish the poster online for our readers and their doctors.
Other than a respiratory infection, I'm having a pain-free day, thanks. Hope you are too!
hugs,
Teri
Hi again, Teri!
It dawned on me later that in my fog I put namenda into the drug category with depakote. Guess I am a little ditsy being on the Depokote (but hopefully not as much as I was on Topamax!).
Cheers,
Clemmie